文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基于四维度磁共振成像技术评估经导管动脉化疗栓塞治疗对肝硬化合并肝细胞癌患者的疗效。

Four-dimensional flow MR imaging for evaluating treatment response after transcatheter arterial chemoembolization in cirrhotic patients with hepatocellular carcinoma.

机构信息

Research Institute of Medical Sciences, Chonnam National University, 264 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do, 58128, Republic of Korea.

Department of Radiology, Chonnam National University Hospital, 42 Jebong-ro, Dong-gu, Gwangju, 61469, Republic of Korea.

出版信息

Radiol Med. 2023 Oct;128(10):1163-1173. doi: 10.1007/s11547-023-01685-8. Epub 2023 Jul 28.


DOI:10.1007/s11547-023-01685-8
PMID:37505380
Abstract

PURPOSE: To prospectively evaluate the potential of four-dimensional (4D) flow magnetic resonance imaging (MRI) in predicting treatment responses after transcatheter arterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma (HCC). METHODS: A total of 195 patients were classified into four groups (A-D): A, cirrhotic patients without HCC (n = 30); B, cirrhotic patients with HCC before TACE (n = 75); C, cirrhotic patients with HCC showing an incomplete response following TACE (n = 56); and D, cirrhotic patients with HCC achieving a complete response (CR) following TACE (n = 34). The patients were subjected to routine laboratory tests and 4D flow MRI using a 3-T MRI system to measure the quantitative parameters of blood flow in the portal vein (PV), splenic vein (SV), and superior mesenteric vein. The data collected by 4D flow MRI were compared among the groups using one-way analysis of variance. A multivariate analysis was performed to verify the association of clinical characteristics and 4D flow parameters with CR after TACE treatment. RESULTS: The average through-plane velocity, peak velocity magnitude, average net flow, peak flow, and net forward volume in the PV and SV were significantly lower in groups B and C (P < 0.05) compared to those in group A. Moreover, average through-plane velocity and peak velocity magnitude in the PV in groups B and C were significantly lower than those in group D (P < 0.05). The multivariate analysis demonstrated that the average through-plane velocity and peak velocity magnitude in the PV were independently associated with CR in HCC patients after TACE (P < 0.05). CONCLUSION: The quantitative flow data obtained by 4D flow MRI may be useful for predicting CR after TACE in cirrhotic patients with HCC.

摘要

目的:前瞻性评估四维(4D)血流磁共振成像(MRI)在预测经导管动脉化疗栓塞(TACE)治疗后肝硬化合并肝细胞癌(HCC)患者治疗反应中的潜力。

方法:共 195 例患者分为 4 组(A-D):A 组为无 HCC 的肝硬化患者(n=30);B 组为 TACE 前有 HCC 的肝硬化患者(n=75);C 组为 TACE 后不完全缓解的肝硬化合并 HCC 患者(n=56);D 组为 TACE 后完全缓解的肝硬化合并 HCC 患者(n=34)。对患者进行常规实验室检查和 3.0T MRI 系统 4D 血流成像,测量门静脉(PV)、脾静脉(SV)和肠系膜上静脉的血流定量参数。采用单因素方差分析比较 4D 血流 MRI 采集的数据。采用多元分析验证 TACE 治疗后临床特征和 4D 血流参数与 CR 的相关性。

结果:与 A 组相比,B 组和 C 组的 PV 和 SV 平均层间速度、峰值速度、平均净流量、峰值流量和净正向容积均显著降低(P<0.05)。此外,B 组和 C 组的 PV 平均层间速度和峰值速度均显著低于 D 组(P<0.05)。多元分析表明,PV 的平均层间速度和峰值速度与 TACE 后 HCC 患者的 CR 独立相关(P<0.05)。

结论:4D 血流 MRI 获得的定量血流数据可能有助于预测 TACE 治疗后肝硬化合并 HCC 患者的 CR。

相似文献

[1]
Four-dimensional flow MR imaging for evaluating treatment response after transcatheter arterial chemoembolization in cirrhotic patients with hepatocellular carcinoma.

Radiol Med. 2023-10

[2]
Value of texture analysis based on enhanced MRI for predicting an early therapeutic response to transcatheter arterial chemoembolisation combined with high-intensity focused ultrasound treatment in hepatocellular carcinoma.

Clin Radiol. 2018-5-24

[3]
Computed tomographic perfusion with 160-mm coverage: comparative analysis of hepatocellular carcinoma treated by two transarterial chemoembolization courses relative to magnetic resonance imaging findings.

Abdom Radiol (NY). 2019-1

[4]
Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.

AJR Am J Roentgenol. 2021-10

[5]
Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.

AJR Am J Roentgenol. 2013-9

[6]
Preoperative MRI features and clinical laboratory indicators for predicting the early therapeutic response of hepatocellular carcinoma to transcatheter arterial chemoembolization combined with High-intensity focused ultrasound treatment.

Br J Radiol. 2019-7

[7]
Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.

Kaohsiung J Med Sci. 2011-5-8

[8]
Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma.

World J Gastroenterol. 2008-10-7

[9]
The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization.

Eur Radiol. 2020-10

[10]
[The quantitative analysis of MR dynamic contrast-enhangced imaging on efficacy and prognosis of transcatheter arterial chemoembolization on hepatocellular carcinoma].

Zhonghua Zhong Liu Za Zhi. 2017-9-23

引用本文的文献

[1]
Radiomics Beyond Radiology: Literature Review on Prediction of Future Liver Remnant Volume and Function Before Hepatic Surgery.

J Clin Med. 2025-7-28

[2]
All You Need to Know About TACE: A Comprehensive Review of Indications, Techniques, Efficacy, Limits, and Technical Advancement.

J Clin Med. 2025-1-7

本文引用的文献

[1]
Hemodynamic changes in the portal vein with age: evaluation using four-dimensional flow MRI.

Sci Rep. 2023-5-6

[2]
Combined MRI and PSA Strategy Improves Biopsy Decisions Compared with PSA Only: Longitudinal Observations of a Cohort of Patients with a PSA Level Less Than 20 ng/mL.

Acad Radiol. 2023-3

[3]
4D Flow MRI in the portal venous system: imaging and analysis methods, and clinical applications.

Radiol Med. 2022-11

[4]
Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria.

Liver Cancer. 2021-7-22

[5]
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.

J Hepatol. 2022-3

[6]
Identification of potential metabolic biomarkers in predicting esophageal varices needing treatment in patients with liver cirrhosis.

Sci Rep. 2021-10-4

[7]
LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma.

Korean J Radiol. 2021-8

[8]
Hepatocellular carcinoma.

Nat Rev Dis Primers. 2021-1-21

[9]
Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells.

Int J Mol Sci. 2020-12-28

[10]
Long-Term Follow-Up of Spinal Stenosis Inpatients Treated with Integrative Korean Medicine Treatment.

J Clin Med. 2020-12-28

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索